Literature DB >> 23886204

Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer.

Yong-Rui Piao1, Long-Zhen Piao, Lian-Hua Zhu, Zhe-Hu Jin, Xiu-Zhe Dong.   

Abstract

BACKGROUND: Optimal treatment for prostate cancer remains a challenge worldwide. Recently, T cell immunoglobulin mucin-3 (TIM-3) has been implicated in tumor biology but its contribution prostate cancer remains unclear. The aim of this study was to investigate the role of TIM-3 as a prognostic marker in patients with prostate cancer.
METHODS: TIM-3 protein expression was determined by immunohistochemistry and Western blotting in 137 prostate cancer tumor samples and paired adjacent benign tissue. We also performed cell proliferation assays using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl- 2H tetrazolium bromide (MTT) and cell invasion assays. The effects of small interfering RNA (siRNA)-mediated knockdown of TIM-3 (TIM-3 siRNA) in two human prostate cancer cell lines were also evaluated.
RESULTS: TIM-3 expression was higher in prostate cancer tissue than in the adjacent benign tissue (P<0.001). High TIM-3 expression was an independent predictor of both recurrence-free survival and progression-free survival. TIM-3 protein was expressed in both prostate cancer cell lines and knockdown suppressed their proliferation and invasion capacity.
CONCLUSIONS: TIM-3 expression is associated with a poor prognosis in prostate cancer. Taken together, our results indicate that TIM-3 is a potential prognostic marker in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23886204     DOI: 10.7314/apjcp.2013.14.6.3897

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  27 in total

Review 1.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

2.  Expression of Tim-3 in breast cancer tissue promotes tumor progression.

Authors:  Shiqing Cheng; Fuyan Han; Yanqiu Xu; Teng Qu; Ying Ju
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

3.  Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.

Authors:  Hualin Zhang; Yang Song; Huimin Yang; Zhiyan Liu; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

Review 4.  Tim-3 and its role in regulating anti-tumor immunity.

Authors:  Madhumita Das; Chen Zhu; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

Authors:  R N Sharan; S Thangminlal Vaiphei; Saibadaiahun Nongrum; Joshua Keppen; Mandahakani Ksoo
Journal:  Cell Oncol (Dordr)       Date:  2015-09-18       Impact factor: 6.730

6.  Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.

Authors:  Encheng Zhou; Qing Huang; Ji Wang; Chengfeng Fang; Leilei Yang; Min Zhu; Jianhui Chen; Lihua Chen; Milian Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 7.  Tim-3 and Tim-4 as the potential targets for antitumor therapy.

Authors:  Lin Cheng; Zhihua Ruan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Advantages of Molecular Weight Identification during Native MS Screening.

Authors:  Ahad Khan; Anne Bresnick; Sean Cahill; Mark Girvin; Steve Almo; Ronald Quinn
Journal:  Planta Med       Date:  2018-05-09       Impact factor: 3.352

Review 10.  Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.

Authors:  Veronica Mollica; Vincenzo Di Nunno; Lidia Gatto; Matteo Santoni; Alessia Cimadamore; Liang Cheng; Antonio Lopez-Beltran; Rodolfo Montironi; Salvatore Pisconti; Nicola Battelli; Francesco Massari
Journal:  Clin Drug Investig       Date:  2019-06       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.